Publications by authors named "Eithne Costello"

Are you Eithne Costello?   Register this Author







Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21.
Oncotarget 2016 Oct;7(41):66328-66343
Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

miRNA dynamics in tumor-infiltrating myeloid cells modulating tumor progression in pancreatic cancer.
Oncoimmunology 2016 Jun 9;5(6):e1160181. Epub 2016 May 9.
Department of Gastroenterology and Endocrinology, University Hospital, Philipps-University, Marburg, Germany; Department of Internal Medicine I, Martin-Luther-University Halle-Wittenberg, Halle, Germany.


Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma.
Br J Cancer 2016 Mar 4;114(5):510-8. Epub 2016 Feb 4.
National Institutes of Health Research Liverpool Pancreas Biomedical Research Unit and Clinical Directorate of General Surgery, Royal Liverpool and Broadgreen University Hospitals NHS Trust and the University of Liverpool, Liverpool L69 3GA, UK.


Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors.
Mol Cancer Ther 2016 Feb 14;15(2):323-33. Epub 2016 Jan 14.
Epithelial Carcinogenesis Group, Cancer Cell Biology Programme, Spanish National Cancer Research Center-CNIO, Madrid, Spain. Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.



Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms.
Clin Cancer Res 2015 May 23;21(10):2325-37. Epub 2015 Feb 23.
Stem Cells and Cancer Group, Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. Centre for Stem Cells in Cancer and Ageing, Barts Cancer Institute, A CR-UK Centre of Excellence, Queen Mary University of London, United Kingdom.

Biomarkers for early diagnosis of pancreatic cancer.
Expert Rev Gastroenterol Hepatol 2015 Mar 6;9(3):305-15. Epub 2014 Nov 6.
Department of Molecular and Clinical Cancer Medicine, National Institute for Health Research Liverpool Pancreas Biomedical Research Unit, University of Liverpool, Daulby Street, Liverpool L69 3GA, UK.

Pancreatic mass in a young CFTR carrier with a heterozygous p.R117H CFTR gene mutation and homozygous 7T.
Pancreas 2015 Mar;44(2):343-5
National Institute for Health Research Liverpool Pancreas Biomedical Research Unit Royal Liverpool University Hospital Liverpool, UK Department of Cellular Pathology Royal Liverpool University Hospital Liverpool, UK National Institute for Health Research Liverpool Pancreas Biomedical Research Unit Royal Liverpool University Hospital Liverpool, UK National Institute for Health Research Liverpool Pancreas Biomedical Research Unit Royal Liverpool University Hospital Liverpool, UK


Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer.
Nat Genet 2014 Sep 3;46(9):994-1000. Epub 2014 Aug 3.
1] Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. [2].


Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
Mol Cancer 2014 May 20;13:114. Epub 2014 May 20.
NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool and Broadgreen University Hospital NHS Trust, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, UK.

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
J Natl Cancer Inst 2014 Jan 3;106(1):djt347. Epub 2013 Dec 3.
Affiliations of authors: Liverpool Cancer Research UK Cancer Trials Unit, Liverpool Cancer Research UK Centre, University of Liverpool, Liverpool, UK (WG, JPN, EG, TFC, PG, EC, CMH, CLR, FC, RJ); the Princess Margaret Hospital, Toronto, Canada (MJM); Manchester Academic Health Sciences Centre, Christie NHS Foundation Trust, School of Cancer and Enabling Sciences, University of Manchester, UK (JWV); Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK (DHP); Beatson West of Scotland Cancer Centre, Glasgow, UK (ACM); Glasgow Royal Infirmary, Glasgow, UK (RC); Hôpital Tenon, Université, Pierre et Marie Curie, Paris, France (FL); Austin Health, Melbourne, Australia (NCT); Prince of Wales Hospital and Clinical School University of New South Wales, New South Wales, Australia (DG); Nepean Cancer Centre and University of Sydney, Sydney, Australia (JS); Agia Olga Hospital, Athens, Greece (CD); Medical Oncology, Clatterbridge Centre for Oncology, Bebington, Merseyside, UK (DS); Department of Oncology, Akademiska Sjukhuset, Uppsala University, Uppsala, Sweden (BG); University Hospital, North Staffordshire, UK (MD); Freeman Hospital, Newcastle upon Tyne, UK (RMC); Service de Chirurgie Digestive et Viscérale, Hôpital Tenon, Paris, France (FL); Cross Cancer Institute and University of Alberta, Alberta, Canada (JRM, AGS); Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, UK (MRM); St James's University Hospital, Leeds, UK (AA); Department of Medicine A, University Medicine Greifswald, Greifswald, Germany (JM); Petz Aladar Hospital, Gyor, Hungary (AO); Departments of Surgery and Pathology and ARC-NET Research Center, University of Verona, Italy (AS, CB); Department of Surgery, University of Heidelberg, Heidelberg, Germany (MWB).

cAMP inhibits migration, ruffling and paxillin accumulation in focal adhesions of pancreatic ductal adenocarcinoma cells: effects of PKA and EPAC.
Biochim Biophys Acta 2013 Dec 22;1833(12):2664-2672. Epub 2013 Jun 22.
Department of Cellular and Molecular Physiology, The University of Liverpool, Crown Street, Liverpool L69 3BX, UK. Electronic address:



Circulating microRNAs as potential markers of human drug-induced liver injury.
Hepatology 2011 Nov;54(5):1767-76
MRC Center for Drug Safety Science, Department of Clinical and Molecular Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.

Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.
Mol Cancer 2011 Apr 13;10:37. Epub 2011 Apr 13.
MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, UK.





Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma.
Gastroenterology 2005 Nov;129(5):1454-63
Molecular Oncology Unit, Cancer Research UK, Barts and The London School of Medicine and Dentistry, John Vane Science Centre, Charterhouse Square, London, United Kingdom.















Designing a bio-inspired biomimetic in vitro system for the optimization of ex vivo studies of pancreatic cancer.
Drug Discov Today 2017 04 30;22(4):690-701. Epub 2017 Jan 30.
Bioprocess and Biochemical Engineering Group (BioProChem), Department of Chemical and Process Engineering, University of Surrey, Guildford GU2 7XH, UK. Electronic address:

OF